Medical Device Market Entry EU vs US: Which Market Should You Enter First?
Choosing between the European Union and the United States as your first medical device market depends on your device classification, regulatory strategy, clinical evidence, available resources, and commercial goals.
In the EU, manufacturers generally follow the EU Medical Device Regulation (EU MDR) and must demonstrate conformity before affixing the CE marking. Depending on the device class and applicable conformity assessment route, a Notified Body may be involved.
In the US, medical devices are regulated by the US Food and Drug Administration (FDA). Depending on the device, manufacturers may follow pathways such as 510(k), De Novo, PMA, or an applicable exemption.
There is no universal answer to which market is easier. The right first market depends on the specific device and the manufacturer’s regulatory and commercial strategy.
Talk to our experts
EU vs US Medical Device Market Entry: Key Differences
| Factor | European Union | United States |
|---|---|---|
| Main framework | EU MDR 2017/745 | Federal Food, Drug, and Cosmetic Act and FDA regulations |
| Regulatory authority | National competent authorities and EU regulatory framework | US FDA |
| Main market access route | CE marking | FDA clearance, approval, exemption, or other applicable pathway |
| Risk classification | Class I, IIa, IIb, III | Class I, II, III |
| Third-party assessment | Notified Body required for many Class IIs and Class III devices and certain Class Is | FDA review depends on applicable pathway |
| Common premarket pathways | Conformity assessment under MDR | 510(k), De Novo, PMA, exemptions and other pathways |
| Quality system | MDR requirements and applicable QMS standards | FDA QMSR, effective February 2, 2026 |
| Post-market requirements | PMS, vigilance, PMCF where applicable | Complaint handling, reporting, surveillance and other applicable controls |
The EU MDR places greater emphasis on lifecycle management, clinical evidence, post-market surveillance and oversight by Notified Bodies.
In the US, the FDA uses a risk-based regulatory system with different marketing pathways depending on the device and its regulatory classification.
Understanding Medical Device Market Entry in the European Union
The European Union regulates medical devices primarily under Regulation (EU) 2017/745, the Medical Device Regulation (MDR).
Manufacturers must determine the applicable device classification and conformity assessment route before placing a device on the EU market.
EU Medical Device Classification
Under the MDR, medical devices are generally classified as:
- Class I
- Class IIa
- Class IIb
- Class III
Classification depends on factors such as intended purpose, duration of use, invasiveness, active or non-active characteristics, and other applicable classification rules.
The classification determines the level of regulatory scrutiny and whether assessment by a Notified Body is required.
CE Marking for Medical Devices
Manufacturers must demonstrate conformity with the applicable MDR requirements before placing their devices on the EU market.
For devices requiring third-party conformity assessment, the manufacturer works with an appropriately designated Notified Body.
The regulatory process can involve:
- Device classification
- Quality management system implementation
- Technical documentation
- Risk management
- Clinical evaluation
- Performance and safety testing
- Labeling and instructions for use
- Conformity assessment
- Declaration of Conformity
- CE marking
- Post-market surveillance
The MDR has strengthened requirements around clinical evidence, lifecycle management and post-market monitoring compared with the previous directives.
Understanding Medical Device Market Entry in the United States
In the United States, medical devices are regulated by the US Food and Drug Administration (FDA).
The FDA uses a risk-based framework to determine the regulatory controls and marketing pathway applicable to a device.
US medical devices are generally classified as:
- Class I
- Class II
- Class III
However, classification alone does not always tell a manufacturer which submission is required. The device’s product code, intended use, technological characteristics, predicate availability and applicable regulations must also be evaluated.
Common FDA Medical Device Market Entry Pathways
1. 510(k)
The FDA 510(k) pathway is commonly used when a device can demonstrate substantial equivalence to a legally marketed predicate device.
The submission can include information such as performance testing, biocompatibility, software validation, electromagnetic compatibility, sterility and other applicable evidence.
2. De Novo
The De Novo pathway may be appropriate for certain novel devices that present low-to-moderate risk and do not have an appropriate predicate device.
3. PMA
Premarket Approval, or PMA, is generally used for higher-risk devices and requires a more extensive demonstration of safety and effectiveness.
4. Exempt Devices
Some lower-risk devices may be exempt from premarket notification, although other FDA requirements can still apply.
Therefore, manufacturers should not assume that every US medical device requires a 510(k).
FDA QMSR: An Important Change for Medical Device Manufacturers
One of the major updates manufacturers should consider when planning US market entry is the FDA’s Quality Management System Regulation (QMSR).
The QMSR became effective on February 2, 2026, replacing the previous Quality System Regulation framework under 21 CFR Part 820 and incorporating ISO 13485:2016 by reference.
This makes a properly implemented medical device quality management system increasingly important for manufacturers preparing for the US market.
Manufacturers should review their QMS, design and development processes, risk management, supplier controls, production controls, complaint handling, records and audit processes against the requirements applicable to their operations.
EU vs US: Which Market Is Easier to Enter?
There is no simple answer.
The better question is:
Which market aligns better with your device, available evidence, business model and long-term expansion strategy?
The EU May Be a Good Starting Point When:
- You plan to sell across multiple European markets.
- Your regulatory strategy is already aligned with EU MDR.
- You have the documentation and clinical evidence needed for your conformity assessment.
- You have identified an appropriate Notified Body where required.
- You want to build a regulatory foundation for other international markets.
The US May Be a Good Starting Point When:
- You have a clear FDA classification and regulatory pathway.
- An appropriate predicate is available for a 510(k).
- Your product has strong technical and performance data.
- Your commercial strategy is strongly focused on the US.
- Your quality system is prepared for FDA requirements and the QMSR.
The decision should ultimately be based on a device-specific regulatory assessment, rather than simply choosing the market with the largest potential revenue.
Clinical Evidence: EU vs US
Clinical and performance evidence is an important part of both regulatory strategies, but the requirements and regulatory expectations differ.
EU
Under the MDR, manufacturers must prepare appropriate clinical evidence to demonstrate conformity with applicable safety and performance requirements.
Depending on the device, this can involve:
- Clinical evaluation
- Clinical investigations
- Literature and equivalent-device evidence where appropriate
- Post-market clinical follow-up
- Post-market surveillance
US
FDA evidence requirements depend on the regulatory pathway.
A 510(k), for example, focuses on demonstrating substantial equivalence to an appropriate predicate, while a PMA requires a more extensive demonstration of safety and effectiveness.
This means manufacturers should determine their regulatory pathway early, because it directly affects the type and amount of evidence they need to generate.
Schedule a Compliance Consultation
Accelerate Market Access with End-to-End Regulatory Guidance
EU vs US Medical Device Market Entry Timeline
Timelines vary significantly from one device to another.
A realistic regulatory plan should account for:
- Product classification
- Regulatory pathway selection
- Gap assessment
- Quality management system preparation
- Technical documentation
- Testing
- Clinical evidence requirements
- Regulatory submission or conformity assessment
- Regulatory review
- Corrections and additional information requests
- Market launch preparation
- Post-market compliance
Manufacturers should avoid using a fixed timeline for all devices. A Class I device and a high-risk Class III device can have substantially different regulatory requirements.
Can EU and US Regulatory Strategies Be Combined?
Yes.
A manufacturer planning global expansion can develop a regulatory strategy that considers both markets from the beginning.
For example, companies can structure their:
- Quality management system
- Risk management documentation
- Design history and development records
- Verification and validation testing
- Clinical evidence strategy
- Technical documentation
- Labeling
- Post-market processes
to support multiple jurisdictions where practical.
However, CE marking does not automatically provide FDA clearance or approval, and FDA clearance does not automatically provide EU market access.
Each market has its own regulatory requirements.
How Operon Strategist Can Help With EU and US Market Entry
Entering a new medical device market requires coordination between regulatory, quality, technical and commercial teams.
Operon Strategist supports medical device manufacturers with regulatory and market entry consulting for the EU, US and other global markets.
Our services can include:
- Medical device classification
- EU MDR and CE marking consulting
- FDA 510(k) consulting
- FDA regulatory pathway assessment
- Quality management system implementation
- ISO 13485 consulting
- Technical documentation
- Risk management documentation
- Clinical and regulatory strategy
- Manufacturing facility consulting
- Regulatory submission support
- Post-market compliance support
- Global medical device market entry planning
Our team can assess your device, target markets and existing documentation to help develop a practical regulatory roadmap.
Plan Your Medical Device Market Entry Strategy
Entering the EU or US market without a clear regulatory strategy can lead to unnecessary testing, documentation gaps, regulatory delays and additional costs.
A structured market entry assessment can help you identify the right regulatory pathway before investing heavily in submissions and commercialization.
Planning to launch your medical device in the EU, US or both?
Talk to Operon Strategist about your product, target market and regulatory requirements.
Ensure Seamless Regulatory Compliance for Your Device
Get Your Medical Device Market-Ready with Expert Regulatory Support
FAQ's
Is it easier to enter the EU or US medical device market?
Neither market is universally easier. The better option depends on your device classification, regulatory pathway, existing evidence, quality system and commercial objectives.
Is CE marking required to sell medical devices in Europe?
For devices within the scope of the EU MDR, manufacturers generally need to demonstrate conformity with the applicable requirements and affix the CE marking before placing the device on the EU market, subject to applicable exceptions and transitional provisions.
Does FDA approval mean my device can be sold in Europe?
No. FDA clearance or approval does not automatically provide authorization to place a medical device on the EU market. The manufacturer must meet applicable EU MDR requirements.
Does CE marking mean FDA approval is not required?
No. A CE mark does not replace applicable FDA requirements for selling a medical device in the United States.
What is the most common FDA pathway for medical devices?
The 510(k) pathway is commonly used for devices with an appropriate legally marketed predicate, but the correct pathway depends on the specific device. Other pathways include De Novo and PMA, as well as applicable exemptions.